Native Probiotic Strain Shows Promise in Chronic Kidney Disease Management
Event summary
- Researchers at Chulalongkorn University have identified Lactobacillus rhamnosus L34, a native probiotic strain, that reduces inflammation and toxin buildup in patients with chronic kidney disease (CKD).
- Clinical trials showed a one-month daily consumption of the probiotic resulted in significant reductions in gut-derived uremic toxins and inflammation-related cytokines without impacting kidney function.
- The probiotic formulation has been patented and production has been assigned to Greater Pharma Co., Ltd., with a powdered form designed for CKD patients’ dietary restrictions.
- Animal model testing demonstrated the probiotic's ability to suppress harmful gut bacteria and reduce inflammation-related markers.
The big picture
The discovery of L34 aligns with the growing trend of leveraging the microbiome to address chronic diseases, offering a potential non-invasive adjunct to existing CKD treatments. While the initial results are promising, the probiotic’s efficacy and long-term impact require further validation. The partnership with Greater Pharma suggests a focus on localized production and accessibility, which could be a key differentiator in the competitive healthcare landscape.
What we're watching
- Long-Term Efficacy
- The impact of prolonged L34 supplementation on CKD progression and patient outcomes warrants investigation, particularly given the potential for gut microbiome adaptation over time.
- Market Adoption
- The success of Greater Pharma’s commercialization efforts will depend on demonstrating cost-effectiveness and accessibility, especially within the Thai healthcare system.
- Regulatory Pathway
- The approval process for microbiome-based therapies remains complex, and the regulatory pathway for L34 in Thailand and potentially other markets will influence its broader adoption.
Related topics